Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 701–800 of 1,000
Krishnan, A. K., Jacobson, S. G., Román, A. J., Iyer, B. S., Garafalo, A. V., Héon, E., & Cideciyan, A. V. (2020) · Vision Research · doi:10.1016/j.visres.2020.01.006 · Cited by 16
“Importantly, successful gene therapy improving visual function in RPE65-LCA has been shown to also improve TPLR in dogs (Acland et al., 2001; Aguirre et al., 2007) and in patients (Cideciyan et al.”
BackgroundSelf-citationLee, E. J., Han, J. C., Park, D. Y., Cho, J., & Kee, C. (2020) · Gene Therapy · doi:10.1038/s41434-020-0166-4 · Cited by 15
Photoreceptor-like cells from reprogramming cultured mammalian RPE cells.
Yan, R., Li, X., Huang, J. Y., Guidry, C., & Wang, S. (2013) · PubMed Central · Cited by 15
Flannery, J. G., & Greenberg, K. P. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.027 · Cited by 16
“…neuroprotection with neurotrophic factors (LaVail et al., 1992) and virus-vector-based delivery of wild-type genes for recessive null mutations (Acland et al., 2001) have come the furthest—to the point of a Phase I/II clinical trial (Hauswirth, 2005) (Jacobson, S., Protocol #0410-677,…”
BackgroundHumphries, M. M., Kenna, P. F., Campbell, M., Tam, L. C. S., Nguyen, A. T. H., Farrar, G. J., Botto, M., Kiang, A. S., & Humphries, P. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.151 · Cited by 15
“In addition, therapeutic modalities have been demonstrated for other genetic subtypes of RP and LCA in a growing number of animal models, both of recessive and dominant forms of disease.(6-23) Notwithstanding such progress, the genetic complexity of this group of diseases represents a formidable logistic and economic…”
BackgroundGenetic markers for retinitis pigmentosa.
Wang, D. Y., Chan, W., Tam, P. O. S., Chiang, S. W. Y., Lam, D. S. C., Chong, K. K. L., & Pang, C. P. (2005) · PubMed · Cited by 15
Clinical trials in retinal dystrophies
Eliott, D., Grob, S., Finn, A. P., & Papakostas, T. (2016) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.173135 · Cited by 21
Kukekova, A. V., Nelson, J. L., Kuchtey, R. W., Lowe, J. K., Johnson, J. L., Ostrander, E. A., Aguirre, G. K., & Acland, G. M. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0861 · Cited by 15
Self-citationJoseph, B., Srinivasan, A., Soumittra, N., Vidhya, A., Shetty, N. S., Uthra, S., & Kumaramanickavel, G. (2002) · Journal of Genetics · doi:10.1007/bf02715866 · Cited by 16
“gene in these patients assumes considerable relevance in the context of a recent report wherein Swedish briard/ briard-beagle dogs with retinal dystrophy due to a defici ency in RPE65 activity owing to a RPE65 –/– genotype (Veske et al. 1999) were successfully treated by gene therapy using adeno-associated viral vecto…”
MethodTissue Bioengineering: Potential Applications to Glaucoma
Young, M. J. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1725 · Cited by 16
“The accessibility of the eye has allowed the retina become something of a proving ground in gene therapy, with clinical trails set to begin in patients with the RPE65 type of Leber congenital amaurosis following the startling success in the dog model of this disease.(54,55) While such a straightforward loss-of-functio…”
BackgroundA Synthetic Rev-Independent Bovine Immunodeficiency Virus-Based Packaging Construct
Molina, R. P., Ye, H. Q., Brady, J. P., Zhang, J., Zimmerman, H. A., Kaleko, M., & Luo, T. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.865 · Cited by 17
Comparison of Voltage Parameters for the Stimulation of Normal and Degenerate Retina
Ye, J. H., & Goo, Y. S. (2007) · Conference proceedings · doi:10.1109/iembs.2007.4353661 · Cited by 15
“Despite a report stating that degenerating mammalian retinas can effectively incorporate rod photoreceptor precursor cells into ONL [7], treatment modalities for the degenerate retina such as gene therapy [8], and retinal transplantation [9] have had only limited success.”
BackgroundThe Treatment of Genetic Disease
Nussbaum, R. L., McInnes, R. R., Willard, H. F., & Hamosh, A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3080-5.50016-x · Cited by 15
Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
“91 This led to a successful multicenter phase I/II clinical trial 92 followed by a phase III trial, which unequivocally showed the efficacy of the treatment in addition to its safety.”
Oshitari, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910485 · Cited by 17
Nelles, M., Stieger, K., Preising, M. N., Kruse, J., & Lorenz, B. (2015) · Ophthalmic Research · doi:10.1159/000435887 · Cited by 15
The Dog Model in the Spotlight: Legacy of a Trustful Cooperation
Barthélémy, I., Hitte, C., & Tiret, L. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190394 · Cited by 19
Noise-induced hearing loss and its prevention: current issues in mammalian hearing
Prell, C. G. L., Hackett, T. A., & Ramachandran, R. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.07.004 · Cited by 16
Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives
Dinculescu, A., Link, B. A., & Saperstein, D. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000378 · Cited by 15
Béhar‐Cohen, F. (2004) · médecine/sciences · doi:10.1051/medsci/2004206-7701 · Cited by 15
“Quelle que soit la stratégie développée (thérapie génique [3, 4], apport de facteurs trophiques [5], anti-proliférants [6], anti-apoptotiques [7, 8], anti-inflammatoires ou anti-infectieux), l’avancée thérapeutique est limitée par l’administration et le ciblage du produit actif.”
BackgroundUltraviolet Light–Induced and Green Light–Induced Transient Pupillary Light Reflex in Mice
Yao, G., Zhang, K., Bellassai, M., Chang, B., & Lei, B. (2006) · Current Eye Research · doi:10.1080/02713680600932308 · Cited by 14
Subramanian, B., Anand, M., Khan, N. W., & Khanna, H. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14954 · Cited by 15
Genome Surgery and Gene Therapy in Retinal Disorders.
Chan, L., Mahajan, V. B., & Tsang, S. H. (2017) · PubMed Central · Cited by 16
Rex, T. S., Peet, J. A., Surace, E. M., Calvert, P. D., Nikonov, S. S., Lyubarsky, A., Bendo, E., Hughes, T. E., Pugh, E. N., & Bennett, J. (2005) · PubMed · Cited by 15
Self-citationLiu, J., Timmers, A. M., Lewin, A. S., & Hauswirth, W. W. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1283 · Cited by 15
“Viral delivery methods and dosages have been established in canines and nonhuman primates, making AAV-mediated gene-silencing plausible in larger animals.(41,42) There are several other implications and potential applications of this technology.”
BackgroundSelf-citationRetinal Remodeling: Circuitry Revisions Triggered by Photoreceptor Degeneration
Marc, R. E., Jones, B. W., & Watt, C. B. (2006) · Springer eBooks · doi:10.1007/0-387-28190-8_3 · Cited by 16
Ultrastructural Telepathology—Remote EM-Diagnostic via Internet
Schroeder, J. A., Voelkl, E., & Hofstaedter, F. (2001) · Ultrastructural Pathology · doi:10.1080/019131201753136322 · Cited by 14
“After the discovery that a microdeletion mutation in a defined gene (RPE65) is responsible for the disease in dogs and primates, a recombinant vector construct AAV-RPE65 (adeno-associated virus -missing cDNA of the RPE65 gene) was injected subretinally into the affected eyes, and restoration of vision was reported [4,…”
BackgroundThe Use of rAAV2-RB1–Mediated Gene Therapy in Retinoblastoma
Shi, H., He, X., Yang, Z. H., Liao, Q., Ruan, J., Ge, S., Chai, P., Jia, R., Fan, J., Wen, X., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.31 · Cited by 16
“17 Through gene replacement or gene editing technology, normal genes are introduced into human cells to treat diseases caused by genetic defects; such strategies precisely target the root cause of these diseases—abnormal DNA—and can often achieve better results than traditional treatments.”
BackgroundGenetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 14
Annear, M. J., Gornik, K. R., Venturi, F. L., Hauptman, J. G., Bartoe, J. T., & Petersen‐Jones, S. M. (2012) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2012.01076.x · Cited by 13
Gillespie, R. L., Lloyd, I. C., & Black, G. C. M. (2014) · Human Heredity · doi:10.1159/000362599 · Cited by 13
Chew, T., Haase, B., Bathgate, R., Willet, C. E., Kaukonen, M. K., Mascord, L. J., Lohi, H., & Wade, C. M. (2017) · G3 Genes Genomes Genetics · doi:10.1534/g3.117.043109 · Cited by 16
“…the dog has become a valuable large animal model for retinal degeneration, in particular, for testing the ef fi cacy of novel therapeutics such as gene therapy (Pearce-Kelling et al. 2001; Acland et al. 2001; Narfström et al. 2003; Cideciyan et al. 2005; Beltran et al. 2012; Pichard et al. 2016).”
Functional Genomics of the Retina to Elucidate its Construction and Deconstruction
Blond, F., & Léveillard, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194922 · Cited by 14
“25 RPE65 Hom NE RPE NF Rare Two No [104] Dog [76]”
BackgroundDisease Mechanisms and Gene Therapy in A Mouse Model for X-Linked Retinoschisis
Molday, L. L., Min, S.-H., Seeliger, M. W., Wu, W. W. H., Dinculescu, A., Timmers, A. M., Janßen, A., Tonagel, F., Hudl, K., Weber, B. H. F., et al. (2007) · Springer eBooks · doi:10.1007/0-387-32442-9_39 · Cited by 13
Self-citationKomáromy, A. M. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.5.714 · Cited by 13
Petersen‐Jones, S. M., Annear, M. J., Bartoe, J. T., Mowat, F. M., Barker, S. E., Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0631-0_24 · Cited by 12
Schlichtenbrede, F. C., Smith, A. J., Bainbridge, J. W., Thrasher, A. J., Salt, T. E., & Ali, R. R. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.09.020 · Cited by 14
Ocular gene therapy trials due to report this year; Keeping an eye on clinical trials in 2008
Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.28 · Cited by 14
What Is Next for Retinal Gene Therapy?
Vandenberghe, L. H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017442 · Cited by 12
“Bundled, these pivotal findings led to a demonstration, in a canine model of the disease, that subretinal injection of AAVencoding a promoter driven cDNA of RPE65 restored objective and behavioral measures of vision (Acland et al. 2001).”
BackgroundAAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Zeng, Y., Qian, H., Wu, Z., Marangoni, D., Sieving, P. A., & Bush, R. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0094-3 · Cited by 12
Self-citationManifestations of systemic disease in the retina and fundus of cats and dogs
Beckwith‐Cohen, B., & Petersen‐Jones, S. M. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1337062 · Cited by 16
Gene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 15
“Additional preclinical studies in rodent and dog models of RPE65 -linked LCA (Jacobson et al., 2006 ; Bennicelli et al., 2008 ; Annear et al., 2011 ), employed AAV for gene delivery but utilized different promoter sequences to drive Ta bl e 1.”
BackgroundInfluentialZobor, D., Brühwiler, B. V. T., Zrenner, E., Weisschuh, N., & Kohl, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108915 · Cited by 16
Recent Advances in Ocular Therapeutics
Whitcup, S. M. (2006) · International Ophthalmology Clinics · doi:10.1097/01.iio.0000212140.70051.33 · Cited by 12
“Investigators successfully used a recombinant adeno-associated virus carrying wild-type RPE65 was used to restore visual function in a dog with the disease, and gene therapy clinical trials are being planned in patients with Leber congenital amaurosis.(9) 2 ’ Whitcup”
MethodComparison of electrically-evoked ganglion cell responses in normal and degenerate retina
Ye, J. H., Kim, K. H., & Goo, Y. S. (2008) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2008.4649699 · Cited by 12
Thompson, S., Mullins, R. F., Philp, A. R., Stone, E. M., & Mrosovsky, N. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1546 · Cited by 12
Molecular genetics of infantile-onset retinal dystrophies
Moradi, P., & Moore, A. T. (2007) · Eye · doi:10.1038/sj.eye.6702843 · Cited by 12
Prevention and therapy in hereditary retinal degenerations
Besch, D., & Zrenner, E. (2003) · Documenta Ophthalmologica · doi:10.1023/a:1022427813898 · Cited by 14
“Recently, gene therapy has been used successfully to improve visual function in dogs with defects in the RPE65 gene, suffering from Lebers’ congenital amaurosis [8].”
BackgroundGene Therapy for Retinal Dystrophies: Twenty Years in the Making
Ali, R. R. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.2506 · Cited by 12
“The first convincing rescues of animal models of retinal disease came at the start of the new millennium (Ali et al., 2000; Acland et al., 2001) and, currently, there is robust proof of concept for gene therapy in approximately two dozen animal models of retinal dystrophy (Smith et al.”
Day blind sheep and the importance of large animal disease models
Komáromy, A. M. (2010) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.07.007 · Cited by 15
Gene editing technology: Towards precision medicine in inherited retinal diseases
Ballios, B. G., Pierce, E. A., & Huckfeldt, R. M. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1887903 · Cited by 13
Bellingrath, J.-S., Li, K. V., Aziz, K., Izzi, J. M., Liu, Y., & Singh, M. S. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2024.1377098 · Cited by 12
Available Evidence on Leber Congenital Amaurosis and Gene Therapy
Alkharashi, M., & Fulton, A. B. (2016) · Seminars in Ophthalmology · doi:10.1080/08820538.2016.1228383 · Cited by 16
Clinical applications of retinal gene therapies
Fu, X., Huu, V. A. N., Duan, Y., Kermany, D., Valentim, C. C. S., Zhang, R., Zhu, J., Zhang, C. L., Sun, X., & Zhang, K. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby004 · Cited by 13
“3).(25) In this study, a subretinal delivery of the canine Rpe65 gene carried by the rAAV2 vector, under the control of the hybrid cytomegalovirus/chicken β-actin (CBA) promoter, resulted in substantial visual improvements as assessed by ERG (Fig.”
MethodOcular gene transfer in the spotlight: implications of newspaper content for clinical communications
Benjaminy, S., & Bubela, T. M. (2014) · BMC Medical Ethics · doi:10.1186/1472-6939-15-58 · Cited by 13
A Practical Approach to Retinal Dystrophies
Tsui, I., Song, B. J., Lin, C., & Tsang, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95046-4_51 · Cited by 11
Gene therapy development in hearing research in China
Zhang, Z., Wang, J., Li, C., Xue, W., Xing, Y., & Liu, F. (2020) · Gene Therapy · doi:10.1038/s41434-020-0177-1 · Cited by 11
Abe, T., Wakusawa, R., Seto, H., Asai, N., Saito, T., & Nishida, K. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0947 · Cited by 13
Increased Expression of MERTK is Associated with a Unique Form of Canine Retinopathy
Ahonen, S., Arumilli, M., Seppälä, E. H., Hakosalo, O., Kaukonen, M. K., Komáromy, A. M., & Lohi, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114552 · Cited by 14
Long-Term Safety of GDNF Gene Delivery in the Retina
Wu, W., Lai, C., Chen, S., Sun, M., Xiao, X., Chen, T.-L., Lin, K., Kuo, S.-W., & Tsao, Y. (2005) · Current Eye Research · doi:10.1080/02713680591005922 · Cited by 12
Gene Delivery by Viral Vectors in Primary Cultures of Lacrimal Gland Tissue
Banin, E., Obolensky, A., Piontek, E., Falk, H., Pikarsky, E., Pe’er, J., Panet, A., & Chowers, I. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0529 · Cited by 11
Which Leber congenital amaurosis patients are eligible for gene therapy trials?
Drack, A. V., Johnston, R., & Stone, E. M. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.08.006 · Cited by 11
“006 In 2001 a dog model of RPE65 LCA was treated with subretinal injection of viral vector bearing a normal copy of the RPE65 gene.(5) This trial was successful in restoring some vision and a recordable electroretinogram in the dog, and these effects have been long-lasting.”
MethodNovel vectors forin vivogene delivery to vascular tissue
White, K., Nicklin, S. A., & Baker, A. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.6.809 · Cited by 12
“AAV2 has a relatively broad tropism and can transduce a wide range of tissues in vivo including muscle, lung, retina [96] and the CNS, but following systemic administration, the majority of the virus is found in the liver [97,98] .”
BackgroundA study of candidate genes for day blindness in the standard wire haired dachshund
Wiik, A. C., Ropstad, E., Bjerkås, E., & Lingaas, F. (2008) · BMC Veterinary Research · doi:10.1186/1746-6148-4-23 · Cited by 11
Gene Therapy with Virus Vectors for specific Disease of the Nervous System
Bosch, A., & Heard, J. M. (2003) · International review of neurobiology · doi:10.1016/s0074-7742(03)01012-2 · Cited by 11
A Comprehensive Study of the Retinal Phenotype of Rpe65-Deficient Dogs
Annear, M. J., Mowat, F. M., Occelli, L. M., Smith, A. J., Curran, P. G., Bainbridge, J. W., Ali, R. R., & Petersen‐Jones, S. M. (2021) · Cells · doi:10.3390/cells10010115 · Cited by 11
“With respect to cone photoreceptor function, other authors have reported no or very low amplitude cone flicker responses in young dogs [13,21,30].”
InfluentialRakoczy, E. P., & Narfström, K. L. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.09.022 · Cited by 11
Bonilha, V. L., Rayborn, M. E., Li, Y., Grossman, G., Berson, E. L., & Hollyfield, J. G. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7973 · Cited by 12
“The sparing of photoreceptors has allowed RPE65 gene replacement therapy to restore this critical retinol isomerase activity to the RPE with the accompanying restoration of visual function.(17,18) In this report we describe the pathology and clinical findings in a woman with a homozygous mutation (Ala132Thr) in the RP…”
BackgroundGene Therapy in the Retinal Degeneration Slow Model of Retinitis Pigmentosa
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_70 · Cited by 12
“AAV vectors are associated with high transduction efficiency, long term gene expression, and after therapeutic delivery to the eye, improvement in retinal function and vision (Acland et al. 2005; Acland et al. 2001).”
BackgroundAdeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 11
Combes, R. D., & Shah, A. B. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400302 · Cited by 14
Bemelmans, A., Kostic, C., Hornfeld, D., Jaquet, M., Crippa, S. V., Hauswirth, W. W., Lem, J., Wang, Z., Schorderet, D. F., Munier, F. L., et al. (2006) · Advances in experimental medicine and biology · doi:10.1007/0-387-32442-9_35 · Cited by 11
Self-citationMao, M., Solivan-Timpe, F., Roos, B. R., Mullins, R. F., Oetting, T. A., Kwon, Y. H., Brzeskiewicz, P. M., Stone, E. M., Alward, W. L. M., Anderson, M. G., et al. (2012) · PubMed Central · Cited by 12
Narfström, K. L., Raymond, M. M., & Seeliger, M. W. (2011) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2011.00915.x · Cited by 11
Rescue of Sight by Gene Therapy—Closer than It May Appear
Rex, T. S. (2007) · Ophthalmic Genetics · doi:10.1080/13816810701503707 · Cited by 11
Ahn, J., Woo, H., Ko, A., Khim, M., Kim, C., Park, N. H., Song, H. Y., Kim, S. W., & Lee, H. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0998-1 · Cited by 10
Retinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus
Hauswirth, W. W. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2530 · Cited by 12
“In collaboration with G. Acland, G. Aguirre, S. Jacobson, and J. Bennett (University Pennsylvania), we employed AAV2 with the CBA promoter driving canine RPE65 cDNA as the first proof of principle for gene therapy in a large animal model of RD (Acland et al., 2001).”
MethodSelf-citationImpact of gene therapy for canine monogenic diseases on the progress of preclinical studies
Switonski, M. (2020) · Journal of Applied Genetics · doi:10.1007/s13353-020-00554-8 · Cited by 12
García-Pérez, L., Ordas, A., Canté-Barrett, K., Meij, P., Pike‐Overzet, K., Lankester, A. C., & Staal, F. J. T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060549 · Cited by 11
Identification of Key Residues Determining Isomerohydrolase Activity of Human RPE65
Takahashi, Y., Moiseyev, G. P., & Ma, J.-X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558619 · Cited by 10
Rédei, G. P., Koncz, C., & Phillips, J. D. (2006) · Advances in genetics · doi:10.1016/s0065-2660(06)56002-x · Cited by 11
Down-regulation of RPE65 protein expression and promoter activity by retinoic acid.
Chen, Y., Ma, J.-X., & Crouch, R. K. (2003) · PubMed · Cited by 13
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
“It enters cells by binding to heparan sulfate, a type of glycosaminoglycan expressed on the surface of host cells, effectively transducing RPE cells (11).”
Clinical and pharmacovigilance safety evaluation of LUXTURNA ® (voretigene neparvovec-rzyl)
Simoens, D., Shravah, V., Jones, W. K., & Kaja, S. (2025) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2025.2573463 · Cited by 13
“A landmark study in Swedish Briard dogs with RPe65 mutations demonstrated the efficacy of AAv-based gene therapy [27–29]. treated puppies (ages 108–132 days) exhibited improved vision, providing evidence of the potential of this therapy for human application [27].”
Opie, N. L., Ayton, L. N., Apollo, N. V., Ganesan, K., Guymer, R. H., & Luu, C. D. (2014) · Artificial Organs · doi:10.1111/aor.12287 · Cited by 9
Fischer, M. D. (2016) · Ophthalmologica · doi:10.1159/000445782 · Cited by 10
Future Vision 2020 and Beyond—5 Critical Trends in Eye Research
Huang, S. S. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000299 · Cited by 10
Matsevich, C., Gopalakrishnan, P., Chang, N., Obolensky, A., Beryozkin, A., Salameh, M., Kostic, C., Sharon, D., Arsenijévic, Y., & Banin, E. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.011 · Cited by 10
Analysis of the Retinal Nerve Fiber Layer in Retinitis Pigmentosa Using Optic Coherence Tomography
Yildirim, M. A., Erden, B., Tetikoğlu, M., Kuru, Ö., & Elçioğlu, M. N. (2015) · Journal of Ophthalmology · doi:10.1155/2015/157365 · Cited by 9
Minella, A., Mowat, F. M., Willett, K. L., Sledge, D. G., Bartoe, J. T., Bennett, J., & Petersen‐Jones, S. M. (2014) · Gene Therapy · doi:10.1038/gt.2014.65 · Cited by 9
“6,7 The aforementioned feline models, along with other spontaneous models currently being characterized (Rah et al ., 8 L Lyons personal communication 2013, and SM Petersen-Jones, unpublished results), show promise for this purpose.”
Self-citationThe Promise of Nanomedicine for Ocular Disease
Thomson, H. A., & Lotery, A. J. (2009) · Nanomedicine · doi:10.2217/nnm.09.43 · Cited by 9
Inherited retinal diseases in dogs: advances in gene/mutation discovery
Miyadera, K. (2014) · The Journal of Animal Genetics · doi:10.5924/abgri.42.79 · Cited by 12
Novel PDE6B Mutation Presenting with Retinitis Pigmentosa – A Case Series of Three Patients
Palmowski-Wolfe, A. M., Štingl, K., Habibi, I., Schorderet, D. F., & Tran, H. V. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0811-5480 · Cited by 10
“reported on the restoration of vision in a dog with RPE65 mutation-induced RP [3].”
BackgroundCRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 14
Stanga, P. E., Tsamis, E., Sisó-Fuertes, I., Dorn, J. D., Merlini, F., Fisher, A., Crawford, F. I. J., Kasbia, S., Papayannis, A., Baseler, H. A., et al. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211000680 · Cited by 10
Emerging biological therapies for age-related macula degeneration
Constable, I. J., Shen, W., & Rakoczy, E. P. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1373 · Cited by 10
“The ready surgical access to the vitreous and to the subretinal space, the proximity of the cells that can be efficiently transduced by rAAV vectors and the known biological characteristics of rAAV-mediated gene transfer in the eye, the minute amounts of gene product and vector required compared with potential gene th…”
BackgroundSpotlight on childhood blindness
Sahel, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58300 · Cited by 9
Gene therapy in glaucoma-3: Therapeutic approaches
Mahdy, M. A.-M. (2010) · Oman Journal of Ophthalmology · doi:10.4103/0974-620x.71883 · Cited by 9
“[15] Diseases caused by mutations that create a gene product destructive to the cell need to be treated using a different approach.”
Terapia gênica em distrofias hereditárias de retina
Côco, M., Han, S. W., & Sallum, J. M. F. (2009) · Arquivos Brasileiros de Oftalmologia · doi:10.1590/s0004-27492009000400026 · Cited by 14
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.